{"id":31410,"date":"2024-05-14T09:00:18","date_gmt":"2024-05-14T07:00:18","guid":{"rendered":"https:\/\/www.cosinuss.com\/?p=31410"},"modified":"2024-05-16T09:49:19","modified_gmt":"2024-05-16T07:49:19","slug":"2nd-digital-biomarker-summit-usa","status":"publish","type":"post","link":"https:\/\/www.cosinuss.com\/en\/2024\/05\/14\/2nd-digital-biomarker-summit-usa\/","title":{"rendered":"2nd Digital Biomarker Summit USA"},"content":{"rendered":"

Date: May 14, 2024<\/strong>
\nTime: 9am – 5pm (GMT-4)<\/strong>
\nLanguage: English<\/strong>
\nLocation: Tarrytown, NY (USA)<\/strong><\/p>\n<\/div>

The renowned biotechnology company Regeneron will host the second Digital Biomarker Summit USA, which will bring together industry thought leaders and decision makers on May 14, 2024 to share updates and new work in the field of digital health technology and digital biomarkers. Dr. Johannes Kreuzer (CEO) will be happy to discuss with participants the use cases and numerous studies in which the cosinuss\u00b0 patient monitoring system has already been successfully used to measure and analyze qualitative health data. We look forward to being part of this pioneering event!<\/p>\n<\/div>

The power of Digital Health Technologies<\/h2><\/div>

The healthcare industry has been working for some time to incorporate digital health technologies (DHTs) into clinical trials and utilize new digital biomarkers. Unlike traditional endpoints, digital biomarkers measure physiological functions through non-invasive, wearable sensors or digital health technologies. This offers numerous advantages, such as objective and quantitative measurements of the pharmacological effects of an investigational drug and more timely and accurate collection of data – often in real time and under real-life conditions. However, there are also new challenges in the development of a scalable framework for digital biomarkers that require interdisciplinary collaboration.
\nThis year’s event will therefore discuss how the industry can collaborate on digital measurements and digital endpoints. Case studies of current work on digital biomarkers in clinical trials will be presented, examples of the role of wearables in the context of AI, digital phenotyping and its impact on observational research will be given, and updates on regulatory readiness for adopting these new measurement approaches will be presented.<\/p>\n<\/div>

Collecting qualitative data with cosinuss\u00b0<\/h2><\/div>

Qualitative data for further processing by AI and ML for clinical studies is essential. After all, no matter how sophisticated the models used may be: If the quality of the data is lacking, the results will not be valid. cosinuss\u00b0 uses sensor technology to provide a large amount of seamlessly recorded and qualitative vital data. With the in-ear sensor c-med\u00b0 alpha and the Health\u00b0 software, the most important vital parameters and other values can be measured and evaluated continuously – remotely or on site. Several studies and projects already show that cosinuss\u00b0 provides high-quality data (e.g. TeleCovid<\/a>, CO-SI-ONKO<\/a>). cosinuss\u00b0 is therefore a valuable partner for collecting and evaluating digital biomarkers. Dr. Johannes Kreuzer is looking forward to exchanging experiences and know-how with the attendees of the 2nd Digital Biomarker Summit. Looking forward to working together on the frontier of clinical discovery!<\/p>\n<\/div>

About Regeneron<\/h2><\/div>

Regeneron, a prominent biotechnology company, pioneers life-changing medicines for severe diseases. With over 35 years of leadership by physician-scientists, Regeneron excels in translating scientific breakthroughs into FDA-approved treatments. Most of their therapies are developed internally. In 2023, Regeneron hosted the first Digital Biomarker Summit USA at its headquarters in Tarrytown, NY.<\/p>\n<\/div>

Further information<\/h2><\/div>

digitalbiomarkersusa.panagorapharma.com<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div>\n

Share this post! \/ Teile diesen Beitrag!<\/div>